Healthcare

  • Medical Device Directive: state of play and future challenges

    The European Institutions have been working on the Directive on Medical Devices and In-Vitro Diagnostics since 2012. With the adoption of the European Parliament’s position in 2013 and the Council agreeing their approach in October 2015, the process has undoubtedly been slow. It was originally hoped that a conclusion would be finally reached by Christmas…

  • mHealth: Harnessing Growth and Innovation

    mHealth is changing the face of healthcare. While its potential is vast, the test for healthcare systems is to capture this value and translate it into concrete results. In our latest snapshot Kyra Obolensky and Lavinia Trehane from FTI Consulting’s healthcare team identify the challenges of building a robust and secure mHealth ecosystem and explore…

  • How to avoid slipping back to the ‘pre-penicillin era’

     This week the European Parliament adopted its own-initiative Report on Safer Healthcare in Europe: Improving Patient Safety and Fighting Antimicrobial Resistance. With this report MEPs are pointing to a looming global health crisis which requires urgent action on many fronts. In our latest snapshot Kyra Obolensky and Darren Kinsella from FTI Consulting’s healthcare team say…

  • What price medicine? A non-Brussels perspective on the EU’s role in shaping medicine prices.

    As part of our Healthy Thinking Series, on Tuesday 05 May FTI Consulting organised a debate on the role of the EU in the pricing and procurement of medicines. In order to broaden our perspective and move away from what can often be a technical debate we invited two speakers from outside the Brussels bubble,…

  • Our office is growing!

    It’s been an exciting start to the year here in Brussels with the addition of seven new team members to strengthen our Competition, Trade and Financial Services practices. The additions include senior professionals from within the European Commission including Massimo Baldinato, John Clancy, Kyra Obolensky and Roeland Van der Stappen as Senior Directors, Robrecht Vandormael…

  • The comeback of forgotten diseases

                      There are many diseases which Europe had presumed to be cured and therefore forgotten. For decades, diseases like polio and tuberculosis (TB) have been associated with developing countries and not those in the EU however recently, we are starting to see a worrying increase in incidents…

  • HTA cooperation at EU level: From “agreeing on to doing”, from therapeutic added value to cost effectiveness

    The heated debate over price transparency before the Christmas break distracted us from another important development which, being often perceived as too technical and theoretical, may in fact result in significant changes for the pharmaceutical industry: EU level cooperation on Health Technology Assessments (HTA) – the method for assessing the ways science & technology are…

  • Can high-priced medicines constitute an abuse of a dominant position in the EU?

    The price of medicines has inevitably always been, and is likely to remain, a long-standing matter of contention between originator companies, governments and patients. It has however become more acute since the launch of some very innovative but very highly priced medicines in recent months, says FTI Consulting’s Darren Kinsella.   Never mind that these…

  • European Commission 2014-2019

    On the 1st November, the 2014-2019 European Commission took office. The new structure, that has been shaped by President Jean-Claude Juncker, consists of seven Vice-Presidents who will steer and coordinate the work of twenty Commissioners. The below overview demonstrates the distribution of responsibilities among the Vice-Presidents and the Commissioners as well as the Heads of…

  • Is the EU moving towards determining healthcare expenditure?

    Something curious is happening with EU health and pharma policies, at a time of the advent of a new European Commission. If one looks at the mission letters of the relevant Commissioners, Vytenis Andriukaitis (Health) and Elżbieta Bieńkowska (Internal Market & Enterprise), the EU health policy agenda is not particularly ambitious. Also, the Commission staff…

Back to top